Four things to know:
1. Third quarter revenue increased 9 percent year-over-year. The uptick was driven by increased adoption of new products, higher procedure volume in the U.S. and strong international sales.
2. NuVasive saw a net loss of $2 million, compared to a net loss of $21.6 million in the third quarter of 2021.
3. The company lowered its 2022 guidance range for net sales from 6 percent to eight percent, to 5.5 percent to 6.5 percent in net sales growth.
4. CEO Chris Barry said, “The strategic investments we’ve made in product and technology innovation are delivering continued above-market growth — as demonstrated by double-digit growth in net sales on a constant currency basis. Despite the challenging macro environment, we continue to execute as evidenced by our top- and bottom-line performance in the quarter.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
